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Abstract
Background: We have previously shown that in the UK mortality in people with Acute Myeloid Leukaemia (AML)
was nearly 50% greater among the most socio-economically deprived. The aim of this study was to determine
whether AML patients from lower socioeconomic classes had a lower chance of receiving a bone marrow
transplant.
Methods: Using Hospital Episode Statistics (HES) data, we identified all incident cases of AML admitted to UK
hospitals between 1998 and 2007. We calculated the number of bone marrow transplantations undertaken in AML
patients, stratifying our results by gender, age at diagnosis, year of diagnosis, degree of socioeconomic deprivation
and co-morbidity. We used logistic regression to calculate odds ratios for bone marrow transplantation, adjusting
for gender, age at diagnosis, year of diagnosis, degree of socioeconomic deprivation and co-morbidity score.
Results: We identified a total of 23 910 incident cases of AML over this 10-year time period, of whom 1 140 (4.8%)
underwent BMT. Bone marrow transplantation declined with increasing socioeconomic deprivation (p for trend
< 0.001) such that people in the most deprived socioeconomic quintile were 40% less likely to have a transplant
than those in the most advantaged group (Odds Ratio 0.60, 95% confidence interval 0.49, 0.73), even after
adjusting for gender, age at diagnosis, year of diagnosis and co-morbidity.
Conclusion: This large cohort study demonstrates that AML patients from lower socioeconomic classes are less
likely to undergo bone marrow transplantation than their better off counter-parts.
Background
We have previously shown that while the incidence of
Acute Myeloid Leukaemia (AML) in the UK is similar
across the spectrum of social class, mortality was nearly
50% greater among the most socioeconomically deprived
patients than among the most advantaged[1]. We postu-
lated that this difference in survival might be due to dif-
ferent patterns of treatment, such as bone marrow
transplantation (BMT), and/or the presence of greater
co-morbidity, such as heart disease and COPD, among
patients from lower socioeconomic classes. Previous stu-
dies have shown that people from more deprived back-
ground are less likely to receive chemotherapy and
radiotherapy for a range of cancers including breast[2],
lung[3] and colorectal[3,4] cancers.
In this study we have used Hospital Episode Statistics
(HES) data to determine whether people with AML
from lower socioeconomic classes are less likely to
receive bone marrow transplantation than those from
higher socioeconomic classes. We also wished to deter-
mine whether any difference in the use of BMT found
was due to greater co-morbidity among more deprived
patients than among the better off.
Methods
We used anonymised hospital episode statistics (HES)
data[5] for this study. These are record-level data admi-
nistered by The NHS Information Centre for Health
and Social Care, on behalf of the Secretary of State for
Health. Data are extracted from routine data flows
between healthcare providers and commissioners and
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dataset, which includes inpatient and day-case records,
was used in this research. Cumulative data are extracted
quarterly for this dataset and it is also updated annually.
The information contained within HES includes patient
demographics such as date of birth, gender and region
of residence, details of diagnoses and treatments
received, as well as administrative details such as admis-
sion and discharge dates, as well as the place patients
were treated (NHS Trust or independent sector hospital,
for example).
We identified all incident cases of AML admitted to
UK hospitals between 1998 and 2007, including those
admitted as day-cases. We also identified all admissions
for co-existing medical diagnoses recorded in HES for
these patients, along with all procedures, including bone
marrow transplantation, which they underwent during
all of their admissions over this period. Bone marrow
transplantation for the purposes of this study means
allogeneic stem cell transplantation with cells harvested
from peripheral blood or bone marrow.
We calculated the number of bone marrow transplan-
tations undertaken in AML patients, stratifying our
results by gender, age at diagnosis, year of diagnosis,
degree of socioeconomic deprivation and co-morbidity.
We used Townsend Score as the measure of socioeco-
nomic deprivation, which is derived from 2001 census
output data and divided into quintiles, with 1 being the
least deprived group and 5 being the most deprived.
The score is based on a combination of four variables
namely: unemployment; car ownership; home ownership
and overcrowding, which produce a ranking of a parti-
cular small homogenous socio-geographic area of about
150 homes[6].
We used co-morbid illness data recorded on admis-
sion to assign a co-morbidity score to each patient using
the Charlson Co-morbidity Index[7]. This scoring takes
into account the presence of 19 different medical disease
groups, each of which carries a weight ranging from 1 to
6, depending on the relative risk of death within
12 months associated with the presence of the particular
disease group. The Charlson Co-morbidity Index has
been found to have good reliability and to correlate well
with mortality[7].
We used logistic regression to calculate odds ratios for
bone marrow transplantation, adjusting for gender, age
at diagnosis, year of diagnosis, degree of socioeconomic
deprivation and co-morbidity score. All data manage-
ment and statistical analyses were conducted using
STATAv.10.0.
Results
We identified a total of 23 910 incident cases of AML
over this 10-year time period, of whom 1 140 (4.8%)
underwent BMT. The numbers of bone marrow trans-
plants performed across various strata in AML are
shown in Table 1. A similar proportion of men and
women had BMT, about 5%. The frequency of bone
marrow transplantation decreased with increasing age at
diagnosis, with only 3 transplants recorded in those
aged 71 or older. A smaller percentage of patients from
lower socioeconomic classes had transplants than those
from higher socioeconomic classes. The relationship
between socioeconomic class and co-morbidity is shown
in Table 2. Between 68 and 70% of AML patients have a
Charlson Co-morbidity Score of 0, 14 -16% have a Score
of 1, and 16% have a Score of 2 or more, with no signif-
icant differences across socio-economic classes in any of
the co-morbidity categories.
Odds Ratios for bone marrow transplantation in AML
a r es h o w ni nT a b l e3 .B o n em a r r o wt r a n s p l a n t a t i o n
declines with increasing age at diagnosis after the age of
30 (p for trend < 0.001), as well as with increasing
Table 1 Numbers of Bone Marrow Transplants
BMT TOTAL
No Yes (%)
Overall 22 770 1 140 (4.8) 23 910
Gender
Males 12 695 614 (4.6) 13 309
Females 10 008 525 (5.0) 10 533
Not Known 67 1 68
Age at Diagnosis
Up to 30 2 909 417(13) 3 326
31 to 40 1 463 213(13) 1 676
41 to 50 1 912 222(10) 2 134
51 to 60 2 947 237(7) 3 184
61 to 70 4 523 48(1) 4 571
71 and older 9 013 3(0) 9 016
Year of Diagnosis
1997 to 1999 4 730 262 (5.2) 4 992
2000 to 2001 4 873 290 (5.6) 5 163
2002 to 2003 4 913 266 (5.1) 5 179
2004 to 2007 8 254 322 (3.8) 8 576
Townsend Score
1 4 433 265 (5.6) 4 698
2 4 495 226 (5.6) 4 721
3 4 179 190 (4.3) 4 396
4 3 968 207 (4.9) 4 175
5 3 735 186 (4.7) 3 921
No Record 1 960 66 (3.3) 2 026
Charlson Co-morbidity Score
0 16 174 855 (5.0) 17 029
1 3 238 108 (3.2) 3 346
2 or more 3 358 177 (5.0) 3 535
Bhayat et al. BMC Cancer 2010, 10:514
http://www.biomedcentral.com/1471-2407/10/514
Page 2 of 5socioeconomic deprivation (p for trend < 0.001).
Patients with AML in the most deprived socioeconomic
quintile are 40% less likely to have a bone marrow
transplantation than those in the most advantaged
socioeconomic class (OR 0.60, p < 0.001, 95% C.I. 0.49,
0.73), even after adjusting for gender, age at diagnosis,
year of diagnosis and co-morbidity. No statistically sig-
nificant interaction was found between Townsend score
and age, or year of diagnosis. There was, however, statis-
tically significant interaction (p = 0.01) between Town-
send score and gender, with greater differences in odds
ratios across the socioeconomic class gradient among
women than men. Results of logistic regression (Odds
Ratios) stratified by gender are shown in Table 4.
Discussion
This study has shown that people with AML from more
deprived socioeconomic classes are less likely to
undergo bone marrow transplantation than their coun-
ter-parts from more advantaged social classes, even after
Table 2 Proportion of AML patients in each category of
Charlson Score by Social Class
Charlson Score
0 1 2 or more
% 95% C.I. % 95% C.I. % 95% C.I.
Townsend Score
1 70 69 - 72 14 13 - 15 16 15 - 17
2 68 67 - 70 16 14 - 17 16 15 - 17
3 69 68 - 71 15 14 - 16 16 15 - 17
4 69 68 - 70 15 14 - 16 16 15 - 17
5 68 67 - 70 16 15 - 17 16 15 - 17
No Record 94 93 - 95 3 2 - 4 2 2 -3
Table 3 Odds Ratios for Bone Marrow Transplantation
Uni-variate Analyses Multi-variate Analyses**
O. R. P>z 95% C.I. O. R. P>z 95% C.I.
Gender
Males 1 - - 1 - -
Females 1.01 0.82 0.92 - 1.11 0.91 0.03 0.83 - 0.99
Age at Diagnosis
Up to 30 1 - - 1 - -
31 to 40 1.02 0.86 0.85 - 1.21 0.86 0.10 0.72 - 1.03
41 to 50 0.82 0.02 0.68 - 0.96 0.65 < 0.001 0.54 - 0.77
51 to 60 0.56 < 0.001 0.47 - 0.66 0.40 < 0.001 0.34 - 0.48
61 to 70 0.07 < 0.001 0.05 - 0.10 0.05 < 0.001 0.04 - 0.07
71 and older 0.00 < 0.001 0.00 - 0.01 0.00 < 0.001 0.00 - 0.00
Year of Diagnosis
1997 to 1999 1 - - 1 - -
2000 to 2001 1.07 0.41 0.90 - 1.28 1.12 0.21 0.94 - 1.34
2002 to 2003 0.98 0.80 0.82 - 1.16 1.11 0.28 0.92 - 1.33
2004 to 2007 0.70 < 0.001 0.60 - 0.83 0.84 0.05 0.70 - 1.00
Townsend Score
11- - 1- -
2 0.84 0.06 0.70 - 1.01 0.85 0.10 0.70 - 1.03
3 0.76 0.01 0.63 - 0.92 0.76 0.01 0.63 - 0.93
4 0.87 0.15 0.72 - 1.05 0.78 0.01 0.64 - 0.95
5 0.83 0.06 *p = 0.1 0.69 - 1.01 0.60 < 0.001 *p < 0.001 0.49 - 0.73
No Record 0.56 < 0.001 0.43 - 0.74 0.18 < 0.001 0.14 - 0.24
Charlson Co-morbidity Score
01- - 1- -
1 0.63 < 0.001 0.51 - 0.77 1.03 0.80 0.83 - 1.27
2 or more 0.99 0.97 0.84 - 1.18 1.58 < 0.001 1.33 - 1.89
*p = test for trend across Townsend Scores 1 to 5.
**Adjusted for gender, age at diagnosis, year of diagnosis Townsend Score and co-morbidity.
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disease.
The main strength of this study is the large size of the
study population. We were able to study over 23 000
incident cases of AML in the UK using data derived
from hospital records. Data also included the co-existing
medical conditions of AML patients, which allowed us
to adjust for co-morbidity. One drawback, however, was
that our data on co-morbidity was based on hospital
admission records for those conditions. This means that
whilst we should have captured the most severe co-mor-
bid illness we will have missed more minor disease. As a
result it is possible that there is some residual con-
founding by co-morbid illness in this study and that
some of the gradient in socioeconomic status and access
to bone marrow transplantation is still due to co-morbid
disease.
By using routinely collected and available data rather
than questionnaires or interviews, we have eliminated
any bias in the reporting of socioeconomic class and any
social class bias in participation in the study. Bone mar-
row transplantation recording is also likely to be accu-
rate in hospital records given the highly specialised
nature of the procedure. It seems likely to us therefore
that the validity of this information is good.
One potential weakness of this study is that we were
unable to adjust for the cytogenetic risk group of our
AML patients. Based on cytogenetics at presentation,
AML patients are classified into good, intermediate, and
adverse risk groups, each with very different long term
outcomes[8]. Good risk patients in their first remission
are not transplanted, whereas adverse risk patients are
almost always transplanted (subject to fitness and donor
availability). Any bias introduced by this in our results,
however, is likely to apply across all social classes, unless
patients from lower social classes are more likely to be
in the good risk group than those from higher socioeco-
nomic classes, for which there is no evidence. Although
there is evidence that patients from lower social classes
present later with disease symptoms in general, it is less
likely that late presentation is an important factor in
AML survival given the acute presentation of the disease
and its relatively poor prognosis. For intermediate risk
patients, however, it is possible that later presentation
may have an impact on the treatment administered and
its outcome.
The accuracy of social class classification is imperfect
given that Townsend Score is not an individual measure
of deprivation. This will have introduced a non-differential
bias into our results, if any, i.e. both patients who had had
ab o n em a r r o wt r a n s p l a n ta n dt h o s ew h oh a dn o tw i l l
have been similarly affected. Such a bias will have moved
odds ratios closer to ‘1’. It seems then that if we had been
able to perfectly adjust for socio-economic deprivation,
our results may have shown an even greater class bias.
The validity of co-morbidity recorded in HES data
may also be imperfect. Any inaccuracies would, how-
ever, apply equally across social class strata and so is
unlikely to have introduced bias into these results.
Furthermore these results showed no difference in
recorded comorbidity across the social classes. Residual
confounding cannot be ruled out completely, however,
since only comorbidity recorded in the hospital episode
data have been taken into account. Other comorbidities
not related to hospital admission or not recorded during
the admission may have existed which would have
resulted in incomplete adjustment for comorbidity.
To our knowledge no studies examining the associa-
tion between bone marrow transplantation and socioe-
conomic class have previously been published. Studies
have, however, examined the associations between social
class and chemotherapy in a number of cancers. Several
studies found that lower socioeconomic class predicted
under-use of chemotherapy in colorectal cancer (CRC)
[3,4], breast cancer[2] and lung cancer[3]. Two North
American studies found that low socioeconomic status
was associated with under-use of adjuvant chemotherapy
in both breast[2] and colorectal cancers[4], and postu-
lated that this was in part due to a combination of poor
access to care, financial barriers and physicians’ assump-
tions and biases regarding patients from lower socioeco-
nomic classes, such as the availability of social and
Table 4 Odds Ratios for Bone Marrow Transplantation
Stratified by Gender
O. R.** P>z 95% C.I.
MALES
Townsend Score
11 - -
2 0.83 0.16 0.63 - 1.08
3 0.77 0.07 0.58 - 1.02
4 0.83 0.17 0.63 - 1.08
5 0.68 0.00 *p = 0.01 0.52 - 0.88
No Record 0.18 < 0.01 0.12 - 0.26
FEMALES
Townsend Score
11 - -
2 0.86 0.29 0.65 - 1.14
3 0.74 0.04 0.56 - 0.98
4 0.73 0.03 0.54 - 0.97
5 0.51 < 0.01 *p < 0.01 0.38 - 0.70
No Record 0.21 < 0.01 0.14 - 0.34
**Adjusted for age at diagnosis, year of diagnosis and Charlson Co-morbidity
Score.
*p = test for trend across Townsend Scores 1 to 5.
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their likely compliance with treatment, for example.
A further study concluded that lower incomes, absent
or limited insurance cover and poorer education
reduced access to high-quality adjuvant chemotherapy,
which in turn reduced survival in breast cancer[9].
In the UK, a Scottish study showed that patients from
the poorest deprivation quintile were less likely to
receive chemotherapy for lung cancer and colorectal
cancer than the most advantaged patients after adjusting
f o ra g e ,t u m o u rs t a g ea td i a g nosis, health authority and
distance from oncology centre[3]. Delay between referral
and treatment was similar across all social classes and
so did not explain the findings. Although this study did
not adjust for comorbidity, another Scottish study which
had done so also found poorer survival in colorectal
cancer patients from the most deprived socioeconomic
quintiles, in a study population which showed no corre-
lation between socioeconomic deprivation and co-mor-
bidity[10]. The findings of these studies, in the UK
healthcare setting where access to treatment is equal
and free, suggest that decision-making (by both physi-
cians and patients) regarding chemotherapy may be
influenced by non-clinical factors.
Conclusions
This large cohort study demonstrates that people with
AML from lower socioeconomic classes in the UK are
less likely to undergo bone marrow transplantation than
their better off counter-parts. Further work is now
required to fully understand the reasons for this finding
and to ensure equal access to treatment for people from
all backgrounds.
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